-
Mashup Score: 4Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy - 2 year(s) ago
Abstract Background Subclinical obstructive valve thrombosis after transcatheter aortic valve replacement (TAVR) is of uncertain frequency and clinical impact. Objectives The aim of this study was …
Categories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 1
ASCO 2022 cabozantinib versus placebo biomarker-negative arm of ATLANTIS, The ATLANTIS trial is an adaptive platform biomarker stratified, multi-arm study of maintenance therapy in patients with metastatic urothelial carcinoma
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
ASCO 2022 final analysis of the ATLANTIS trial randomized, double blind phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma, standard treatment for advanced urothelial carcinoma
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 4
This editorial refers to ‘Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial’, by J.-P. Collet et al., https://doi.
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3ASCO GU 2022: Discussion on the ATLANTIS and BAYOU Trials in Advanced Urothelial Cancer - 2 year(s) ago
ASCO GU 2022 ATLANTIS trial, BAYOU trial, the rucaparib arm of the ATLANTIS trial among patients with metastatic urothelial carcinoma (mUC), BAYOU, examining durvalumab and olaparib as first-line therapy in platinum-ineligible patients with unresectable stage IV urothelial carcinoma.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2
ASCO GU 2022 results of the rucaparib arm of the ATLANTIS trial among patients with metastatic urothelial carcinoma, switch maintenance with the PARP inhibitor rucaparib would improve outcomes for patients who had derived benefit from platinum-based chemotherapy metastatic urothelial carcinoma,
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
A randomized, double blind, biomarker selected, P II clinical trial of maintenance PARP inhibition following chemotherapy for #mUC: Final analysis of the #ATLANTIS rucaparib arm. Presented by Simon Crabb, PhD, MBBS. #GU22 coverage by @WallisCJD > https://t.co/jXmI4uzYix @ECMC_UK https://t.co/lvTJYbTRvG
-
-
Mashup Score: 3
Future research needs to consider the longer-term impact of thrombus and whether certain patient subsets could benefit.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
Future research needs to consider the longer-term impact of thrombus and whether certain patient subsets could benefit.
Source: TCTMD.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 13Oral Anti-xa Anticoagulation After Trans-aortic Valve Implantation For Aortic Stenosis: The Randomized Atlantis Trial - tctmd.com - 3 year(s) ago
Specialty Menu Navigation COVID-19 Clinical Coronary Structural Endovascular …
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
My @TCTMD LBT with Jean Phillipe Collet aboiut the #ATLANTIS trial and personalisation of antithormbotic regimes post #TAVR https://t.co/Zi0ujjqaDx @aayshacader @mirvatalasnag @HanCardiomd @ShelleyWood2 @ekgpdx @HarryDauerman @djc795 @Almanfi_Cardio @adnanalkhouli @purviparwani https://t.co/a1OV05fXxp
-
-
Mashup Score: 3
Future research needs to consider the longer-term impact of thrombus and whether certain patient subsets could benefit.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet
The #ATLANTIS-4D-CT RCT sub-study shows #apixaban reduces subclinical obstructive valve thrombosis in patients undergoing #TAVR without an indication for anticoagulation. https://t.co/FULeq7fycu #JACCINT #CardioTwitter @ActionCoeur https://t.co/1TlwAt79aI